Clinical trials: AD - Alzheimer's Disease
Alzheimer Disease, Caregiver Burden
Voice and Swallowing Disorders in Adults With and Without Alzheimer's Disease
This research study is investigating whether people with Alzheimer's disease experience more changes to voice and swallowing than their healthy age-matched peers.
- Conditions
- Alzheimer Disease, Caregiver Burden, Healthy Aging, Dysphonia
- Trial name
- NCT06328374
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Alzheimer Disease
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
The purpose of this study is to evaluate the long-term safety and tolerability of JNJ-54861911 in participants in the early Alzheimer's disease (AD [progressive brain disease that slowly destroys memory and thinking skills, and…
- Trial name
- NCT02406027
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 25 mg, JNJ-54861911, 5 mg
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 90 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease(AD)
12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
This is a 12-month, single-arm, real-world study designed to evaluate the efficacy and safety of lecanemab (10 mg/kg administered every two weeks) in patients with early Alzheimer's disease, including mild cognitive impairment…
- Trial name
- NCT07034222
- Testing
- Administer Leqemi 10 mg/kg, every two weeks.
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Ruijin Hospital
Alzheimer's Disease
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more…
- Trial name
- NCT05908695
- Testing
- GV-971
- Where
- 50 sites in China
- Volunteers
- 1,312 people
- Sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer Disease
TMS Pilot in Early AD II
Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 6.2 million individuals in the United States, resulting in an annual cost of care of $305 billion.
- Trial name
- NCT06817902
- Testing
- Intermittent theta burst stimulation active coil
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- HealthPartners Institute
Alzheimer's Disease
Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
The study is a randomized, parallel, 4-dose design in subjects with mild-to-moderate Alzheimer's Disease. Subjects will be randomized to one of 4 doses of T3D-959.
- Trial name
- NCT02560753
- Testing
- T3D-959
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- T3D Therapeutics, Inc.
Alzheimer Disease
Vielight Neuro RX Gamma - Feasibility Pilot
This study tests the effects of the Neuro RX Gamma synchronous and asynchronous devices on the cognitive and behavioral functioning of subjects with moderate-to-severe Alzheimer's Disease.
- Trial name
- NCT03328195
- Testing
- Neuro RX Gamma synchronous, Neuro RX Gamma asynchronous
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Vielight Inc.
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease
The purposes of this study are to determine: The safety of LY450139 dihydrate and any side effects that might be associated with it. How much LY450139 dihydrate should be given and how long it may be detected in blood.
- Trial name
- NCT00244322
- Testing
- LY450139 dihydrate
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Differential Effects of Various Anesthetic Agents on Cognitive Function in Patients With Alzheimer's Disease
The objective of the study is to determine the effects of different anesthetic agents on cognitive function in patients with Alzheimer's disease (AD).
- Trial name
- NCT01870453
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimer's Disease
Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects
This is a Phase 1, Randomized, Placebo-Controlled, Double-Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects.
- Trial name
- NCT01467726
- Testing
- Velusetrag
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alfasigma S.p.A.
Alzheimer's Disease
ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)
The study is designed to investigate the activity of the hormone drug leuprolide acetate in stabilizing cognitive function in mild-to-moderate AD patients.
- Trial name
- NCT00231946
- Testing
- VP4896
- Where
- 59 sites in United States, Canada
- Volunteers
- 555 people
- Sponsor
- Voyager Pharmaceutical Corporation
Alzheimer Disease
Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease
The steroid pregnenolone sulfate (PREGS) may be one of the factors responsible for the memory decline related to normal aging or associated with Alzheimer's disease (AD).
- Trial name
- STERMEM (NCT00912886)
- Where
- 6 sites in France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sleep, Alzheimer Disease
A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers
Studies consistently show the negative health impact of sleep problems in both Alzheimer's disease (AD) patients and their caregivers.
- Trial name
- NCT03455569
- Testing
- Behavioral sleep education, Education only
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of California, Los Angeles
Alzheimer Disease
Non-invasive Stimulation Through Nesa and Therapeutic Exercise on Sleep Disturbances on Alzheimer's Disease Patients.
The purpose of this study is to know the effectiveness of an adapted therapeutic exercise program and its comparison with non-invasive neuromodulation through the NESA device, and both treatments with a control group, to improve…
- Trial name
- NCT05715866
- Testing
- non-invasive neuromodulation through the Nesa device, therapeutic exercise, sleep hygiene measures
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Universidad de Murcia
Alzheimer Disease, Healthy Aging
Telerehabilitation Alzheimer's Disease Usability (TADU)
Usability evaluation of BrightGo cognitive telerehabilitation system. An experimental system was developed to enhance standard of care (medication effect) for Early Alzheimer's Disease populations.
- Trial name
- TADU (NCT04731311)
- Testing
- Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Bright Cloud International Corp
Mild Cognitive Impairment (MCI), Alzheimer Disease
Speech-derived Digital Biomarkers Study
The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD).
- Trial name
- NCT06994767
- Testing
- The Canary Application
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Hackensack Meridian Health
Alzheimers Disease
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in…
- Trial name
- GS1 (NCT02565511)
- Testing
- CAD106 Immunotherapy, CNP520, Alum
- Where
- 129 sites in United States, Australia and 8 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer's disease (AD) is the main cause of dementia. At present, AD is incurable. Cholinesterase inhibitors, especially donepezil, are the first choice for mild and moderate AD.
- Trial name
- NCT05114499
- Testing
- Donepezil, GV-971
- Volunteers
- 150 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Alzheimer's Disease
Effects of Simvastatin on Biomarkers
A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.
- Trial name
- SimBio (NCT01142336)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Washington
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.